SDK1-ALK Fusion in a Lung Adenocarcinoma Patient With Excellent Response to ALK Inhibitor Treatment: A Case Report

BACKGROUND: Rearrangements of Anaplastic lymphoma kinase (ALK) have been discovered as a novel driver mutation in patients with non–small-cell lung cancer (NSCLC). Patients’ responses to ALK tyrosine kinase inhibitors (TKIs) may vary depending on the variations of ALK rearrangements they have. It is...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Lin, Xiao, Junjuan, Guan, Yaping, Wu, Dongfang, Gu, Tiantian, Wang, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8931607/
https://www.ncbi.nlm.nih.gov/pubmed/35311071
http://dx.doi.org/10.3389/fonc.2022.860060

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8931607/
https://www.ncbi.nlm.nih.gov/pubmed/35311071
http://dx.doi.org/10.3389/fonc.2022.860060

Ejemplares similares